title: Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function.
abstract: The paramyxovirus simian virus 5 (SV5) is a poor activator of human dendritic cell (DC) maturation pathways in vitro, and infected DC do not upregulate cell surface costimulatory proteins or secretion of immunomodulatory cytokines. We evaluated the hypothesis that activation of SV5-infected DC would be enhanced by engineering SV5 to express a Toll-like-receptor (TLR) ligand. To test this hypothesis, a novel virus was engineered such that the gene encoding an intracellular form of the TLR5 ligand flagellin was expressed from the genome of wild-type (WT) SV5 (SV5-flagellin). Cells infected in vitro with the flagellin-expressing virus released low levels of biologically active flagellin, which was capable of stimulating TLR5 signaling. Infection of human peripheral blood mononuclear cell-derived immature DC with SV5-flagellin resulted in enhanced levels of interleukin-6 (IL-6) and IL-12 compared to infection with DC with the parental virus, WT SV5. In contrast to cytokine induction, the flagellin-expressing virus did not appreciably increase DC surface expression of the costimulatory molecule CD80 or CD86 above the level seen with WT SV5 alone. In mixed-culture assays, DC infected with the flagellin-expressing virus were more effective at activating gamma interferon secretion from both CD8(+) and CD4(+) allogeneic T cells than DC infected with WT SV5. Our results with SV5-directed intracellular expression of flagellin may be applicable to other vectors or pathogenic viruses where overcoming impairment of DC activation could contribute to the development of safer and more effective vaccines.
authors.affiliation: Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1064, USA.
authors.forename: Subhashini
authors.initials: S
authors.lastname: Arimilli
authors.forename: John B
authors.initials: JB
authors.lastname: Johnson
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Clark
authors.forename: Aaron H
authors.initials: AH
authors.lastname: Graff
authors.forename: Martha A
authors.initials: MA
authors.lastname: Alexander-Miller
authors.forename: Steven B
authors.initials: SB
authors.lastname: Mizel
authors.forename: Griffith D
authors.initials: GD
authors.lastname: Parks
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics / Q000494:pharmacology*; D018122:B7-1 Antigen / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D005408:Flagellin / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D018664:Interleukin-12 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D045402:Parainfluenza Virus 5 / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000494:pharmacology; D011995:Recombination, Genetic; D051198:Toll-Like Receptor 5 / Q000276:immunology* / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D018122:B7-1 Antigen; D015850:Interleukin-6; D011994:Recombinant Proteins; C495346:TLR5 protein, human; D051198:Toll-Like Receptor 5; D005408:Flagellin; D018664:Interleukin-12
references.citation: Vaccine. 1996 Jan;14(1):85-92
references.pmid: 8821654
references.citation: J Exp Med. 1997 Sep 15;186(6):801-12
references.pmid: 9294135
references.citation: Vaccine. 2008 Jan 10;26(2):201-14
references.pmid: 18063235
references.citation: J Gen Virol. 2002 May;83(Pt 5):1167-1172
references.pmid: 11961272
references.citation: Virology. 2008 Jul 5;376(2):416-28
references.pmid: 18456301
references.citation: J Immunol. 2004 Mar 1;172(5):2861-9
references.pmid: 14978087
references.citation: J Virol. 2005 May;79(9):5507-15
references.pmid: 15827165
references.citation: J Virol. 2006 Apr;80(7):3128-34
references.pmid: 16537581
references.citation: Virology. 2007 Aug 15;365(1):144-56
references.pmid: 17459446
references.citation: J Virol. 2008 Jan;82(2):828-39
references.pmid: 17977969
references.citation: J Virol. 2006 Jul;80(13):6295-304
references.pmid: 16775317
references.citation: J Immunol. 1999 Dec 15;163(12):6762-8
references.pmid: 10586075
references.citation: J Immunol. 2003 May 15;170(10):5165-75
references.pmid: 12734364
references.citation: J Virol. 2007 Oct;81(20):11116-27
references.pmid: 17686837
references.citation: Virology. 2007 May 25;362(1):139-50
references.pmid: 17254623
references.citation: J Virol. 2002 Oct;76(20):10109-21
references.pmid: 12239285
references.citation: J Virol. 1999 Dec;73(12):9928-33
references.pmid: 10559305
references.citation: Infect Immun. 2000 Oct;68(10):5525-9
references.pmid: 10992449
references.citation: Blood. 2002 Apr 15;99(8):2913-21
references.pmid: 11929782
references.citation: Mech Ageing Dev. 2008 May;129(5):271-81
references.pmid: 18367233
references.citation: Immunity. 2001 May;14(5):495-8
references.pmid: 11371351
references.citation: J Virol. 2006 Nov;80(21):10293-306
references.pmid: 17041210
references.citation: Nat Immunol. 2000 Nov;1(5):398-401
references.pmid: 11062499
references.citation: Nat Immunol. 2005 Feb;6(2):163-70
references.pmid: 15654341
references.citation: Nature. 2001 Oct 18;413(6857):732-8
references.pmid: 11607032
references.citation: Nature. 2001 Apr 26;410(6832):1099-103
references.pmid: 11323673
references.citation: Nat Immunol. 2004 Oct;5(10):987-95
references.pmid: 15454922
references.citation: J Virol. 2004 Aug;78(15):7867-73
references.pmid: 15254159
references.citation: Infect Immun. 2004 Nov;72(11):6676-9
references.pmid: 15501801
references.citation: J Virol. 2006 Apr;80(7):3416-27
references.pmid: 16537609
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5598-603
references.pmid: 15034168
references.citation: Virology. 1964 Jun;23:224-33
references.pmid: 14192298
references.citation: J Virol. 2005 Jan;79(1):401-9
references.pmid: 15596833
references.citation: Virology. 2002 Nov 10;303(1):15-32
references.pmid: 12482655
references.citation: Nat Immunol. 2006 Jun;7(6):549-51
references.pmid: 16715062
references.citation: J Virol. 2003 Apr;77(8):4588-96
references.pmid: 12663765
references.citation: J Gen Virol. 1999 Apr;80 ( Pt 4):823-833
references.pmid: 10211949
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: Nat Med. 2007 May;13(5):552-9
references.pmid: 17479101
references.citation: J Biol Chem. 2005 Mar 11;280(10):9482-8
references.pmid: 15632166
references.citation: J Virol. 2003 Jun;77(12):7124-30
references.pmid: 12768033
references.citation: J Infect Dis. 2003 Dec 1;188(11):1630-8
references.pmid: 14639532
references.citation: J Virol. 2002 Sep;76(17):8729-36
references.pmid: 12163593
references.citation: Immunol Res. 2005;33(1):83-101
references.pmid: 16120974
references.citation: J Exp Med. 1999 Apr 19;189(8):1315-28
references.pmid: 10209048